Hemorrhagic Complications in Pediatric Hematologic Malignancies

 

 Buy Article Permissions and Reprints

ABSTRACT

Hematologic malignancies account for almost 40% of all cancers in children. Hemorrhage is the most common cause of early death in children with leukemia. Furthermore, major bleeding episodes lead to shorter survival and increased resource use. Potential risk factors for bleeding include hyperleukocytosis, immunophenotype of leukemia (especially acute promyelocytic leukemia), thrombocytopenia, and associated infections. Successful management of a bleeding episode is dependent on prompt identification of a child at high risk for bleeding, and should be directed at the replacement of blood products as well as to the aggressive therapy for underlying risk factors. Although in recent years there is a favorable decline in the hemorrhage-related mortality, the overall prevalence and the extent of morbidity posed by this potentially fatal complication, including disease outcome in children with hematologic malignancy, is largely unknown. In addition, there are no evidence-based guidelines for prophylactic blood or blood product transfusions. Prospective studies are required to define the epidemiology and risk factors predisposing children with hematologic malignancy to bleeding and to develop management guidelines.

REFERENCES

• 1 Canada NCI .Canadian Cancer Statistics. Toronto; NCI 69-71
  Google Scholar
• 2 Smith M. Childhood cancer: Incidence, survival, and mortality. In: Pizzo P Principles and Practice of Pediatric Oncology. Philadelphia, PA; Lippincott Williams & Wilkins 2002: 1-12
  Google Scholar
• 3 Sandlund J T, Downing J R, Crist W M. Non-Hodgkin's lymphoma in childhood.  N Engl J Med. 1996;  334 1238-1248
  CrossrefPubMedGoogle Scholar
• 4 Slats A M, Egeler R M, van der Does-van den Berg A et al.. Causes of death-other than progressive leukemia-in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience.  Leukemia. 2005;  19 537-544
  PubMedGoogle Scholar
• 5 Brenner B, Hoffman R, Balashov D, Shutluko E, Culic S D, Nizamoutdinova E. Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated factor VII.  Clin Appl Thromb Hemost. 2005;  11 401-410
  CrossrefPubMedGoogle Scholar
• 6 Rubnitz J E, Lensing S, Zhou Y et al.. Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience.  Cancer. 2004;  101 1677-1684
  CrossrefPubMedGoogle Scholar
• 7 Wheeler K, Chessells J M, Bailey C C, Richards S M. Treatment related deaths during induction and in first remission in acute lymphoblastic leukaemia: MRC UKALL X.  Arch Dis Child. 1996;  74 101-107
  PubMedGoogle Scholar
• 8 Liang D C, Hung I J, Yang C P et al.. Unexpected mortality from the use of E. coli L-asparaginase during remission induction therapy for childhood acute lymphoblastic leukemia: a report from the Taiwan Pediatric Oncology Group.  Leukemia. 1999;  13 155-160
  CrossrefPubMedGoogle Scholar
• 9 Riley L C, Hann I M, Wheatley K, Stevens R F. Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party.  Br J Haematol. 1999;  106 436-444
  CrossrefPubMedGoogle Scholar
• 10 Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.  J Clin Oncol. 2004;  22 4384-4393
  CrossrefPubMedGoogle Scholar
• 11 Creutzig U, Zimmermann M, Ritter J et al.. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.  Leukemia. 2005;  19 2030-2042
  CrossrefPubMedGoogle Scholar
• 12 O'Brien T A, Russell S J, Vowels M R et al.. Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group.  Blood. 2002;  100 2708-2716
  CrossrefPubMedGoogle Scholar
• 13 Clavell L A, Gelber R D, Cohen H J et al.. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia.  N Engl J Med. 1986;  315 657-663
  PubMedGoogle Scholar
• 14 Ribeiro R C, Pui C H. The clinical and biological correlates of coagulopathy in children with acute leukemia.  J Clin Oncol. 1986;  4 1212-1218
  PubMedGoogle Scholar
• 15 Wermes C, von Depka Prondzinski M, Lichtinghagen R, Barthels M, Welte K, Sykora K W. Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters.  Eur J Pediatr. 1999;  158(suppl 3) S143-S146
  CrossrefPubMedGoogle Scholar
• 16 Woods W G, Kobrinsky N, Buckley J D et al.. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group.  Blood. 1996;  87 4979-4989
  PubMedGoogle Scholar
• 17 Kim H, Lee J H, Choi S J, Kim W K, Lee J S, Lee K H. Analysis of fatal intracranial hemorrhage in 792 acute leukemia patients.  Haematologica. 2004;  89 622-624
  PubMedGoogle Scholar
• 18 Goad K E, Gralnick H R. Coagulation disorders in cancer.  Hematol Oncol Clin North Am. 1996;  10 457-484
  CrossrefPubMedGoogle Scholar
• 19 Wilde J T, Davies J M. Haemostatic problems in acute leukaemia.  Blood Rev. 1990;  4 245-251
  CrossrefPubMedGoogle Scholar
• 20 Quinones-Hinojosa A, Gulati M, Singh V, Lawton M T. Spontaneous intracerebral hemorrhage due to coagulation disorders.  Neurosurg Focus. 2003;  15 1-15
  PubMedGoogle Scholar
• 21 Kyrnetskiy E E, Kun L E, Boop F A, Sanford R A, Khan R B. Types, causes, and outcome of intracranial hemorrhage in children with cancer.  J Neurosurg. 2005;  102 31-35
  PubMedGoogle Scholar
• 22 Ott N, Ramsay N K, Priest J R et al.. Sequelae of thrombotic or hemorrhagic complications following L-asparaginase therapy for childhood lymphoblastic leukemia.  Am J Pediatr Hematol Oncol. 1988;  10 191-195
  CrossrefPubMedGoogle Scholar
• 23 Soylu A R, Buyukasik Y, Cetiner D et al.. Overt gastrointestinal bleeding in haematologic neoplasms.  Dig Liver Dis. 2005;  37 917-922
  CrossrefPubMedGoogle Scholar
• 24 Schwartz J M, Wolford J L, Thornquist M D et al.. Severe gastrointestinal bleeding after hematopoietic cell transplantation, 1987-1997: incidence, causes, and outcome.  Am J Gastroenterol. 2001;  96 385-393
  PubMedGoogle Scholar
• 25 Jackson N, Reddy S C, Hishamuddin M, Low H C. Retinal findings in adult leukaemia: correlation with leukocytosis.  Clin Lab Haematol. 1996;  18 105-109
  CrossrefPubMedGoogle Scholar
• 26 Reddy S C, Quah S H, Low H C, Jackson N. Prognostic significance of retinopathy at presentation in adult acute leukemia.  Ann Hematol. 1998;  76 15-18
  CrossrefPubMedGoogle Scholar
• 27 Reddy S C, Menon B S. A prospective study of ocular manifestations in childhood acute leukaemia.  Acta Ophthalmol Scand. 1998;  76 700-703
  CrossrefPubMedGoogle Scholar
• 28 Reddy S C, Jackson N. Retinopathy in acute leukaemia at initial diagnosis: correlation of fundus lesions and haematological parameters.  Acta Ophthalmol Scand. 2004;  82 81-85
  CrossrefPubMedGoogle Scholar
• 29 Rogers Z. Hematologic supportive care. In: Pizzo P Principles and Practice of Pediatric Oncology. Philadelphia; Lippincott Williams & Wilkins 2002: 1205-1238
  Google Scholar
• 30 Wehmeier A, Sudhoff T, Meierkord F. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.  Semin Thromb Hemost. 1997;  23 391-402
  PubMedGoogle Scholar
• 31 Behm F. Manifestations of the bone marrow. In: Parham D Pediatric Neoplasia: Morphology and Biology. Philadelphia; Lippincott-Raven 1996: 449-504
  Google Scholar
• 32 Falanga A, Barbui T. Coagulopathy of acute promyelocytic leukemia.  Acta Haematol. 2001;  106 43-51
  CrossrefPubMedGoogle Scholar
• 33 Tallman M S, Andersen J W, Schiffer C A et al.. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.  Blood. 2002;  100 4298-4302
  CrossrefPubMedGoogle Scholar
• 34 Ucar C, Caliskan U. Successful treatment of acute lymphoblastic leukemia with L-asparaginase-induced intracranial hemorrhage to activated recombinant factor VIIa in a child.  Pediatr Hematol Oncol. 2006;  23 339-345
  CrossrefPubMedGoogle Scholar
• 35 Sanz M A. Treatment of acute promyelocytic leukemia.  Hematology (Am Soc Hematol Educ Program). 2006;  147-155
  PubMedGoogle Scholar
• 36 Gmur J, Burger J, Schanz U, Fehr J, Schaffner A. Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia.  Lancet. 1991;  338 1223-1226
  CrossrefPubMedGoogle Scholar
• 37 Callow C R, Swindell R, Randall W, Chopra R. The frequency of bleeding complications in patients with haematological malignancy following the introduction of a stringent prophylactic platelet transfusion policy.  Br J Haematol. 2002;  118 677-682
  CrossrefPubMedGoogle Scholar
• 38 Gil-Fernandez J J, Alegre A, Fernandez-Villalta M J et al.. Clinical results of a stringent policy on prophylactic platelet transfusion: non-randomized comparative analysis in 190 bone marrow transplant patients from a single institution.  Bone Marrow Transplant. 1996;  18 931-935
  PubMedGoogle Scholar
• 39 Heckman K D, Weiner G J, Davis C S, Strauss R G, Jones M P, Burns C P. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL.  J Clin Oncol. 1997;  15 1143-1149
  PubMedGoogle Scholar
• 40 Howard S C, Gajjar A J, Cheng C et al.. Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia.  JAMA. 2002;  288 2001-2007
  CrossrefPubMedGoogle Scholar
• 41 Vavricka S R, Walter R B, Irani S, Halter J, Schanz U. Safety of lumbar puncture for adults with acute leukemia and restrictive prophylactic platelet transfusion.  Ann Hematol. 2003;  82 570-573
  CrossrefPubMedGoogle Scholar
• 42 Howard S C, Gajjar A, Ribeiro R C et al.. Safety of lumbar puncture for children with acute lymphoblastic leukemia and thrombocytopenia.  JAMA. 2000;  284 2222-2224
  CrossrefPubMedGoogle Scholar
• 43 Priest J R, Ramsay N K, Bennett A J, Krivit W, Edson J R. The effect of L-asparaginase on antithrombin, plasminogen, and plasma coagulation during therapy for acute lymphoblastic leukemia.  J Pediatr. 1982;  100 990-995
  PubMedGoogle Scholar
• 44 Legnani C, Palareti G, Pession A et al.. Intravascular coagulation phenomena associated with prevalent fall in fibrinogen and plasminogen during L-asparaginase treatment in leukemic children.  Haemostasis. 1988;  18 179-186
  PubMedGoogle Scholar
• 45 Ramsay N K, Coccia P F, Krivit W, Nesbit M E, Edson J R. The effect of L-asparaginase of plasma coagulation factors in acute lymphoblastic leukemia.  Cancer. 1977;  40 1398-1401
  CrossrefPubMedGoogle Scholar
• 46 Homans A C, Rybak M E, Baglini R L, Tiarks C, Steiner M E, Forman E N. Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia.  J Clin Oncol. 1987;  5 811-817
  PubMedGoogle Scholar
• 47 Halton J M, Mitchell L G, Vegh P, Eves M, Andrew M E. Fresh frozen plasma has no beneficial effect on the hemostatic system in children receiving L-asparaginase.  Am J Hematol. 1994;  47 157-161
  CrossrefPubMedGoogle Scholar
• 48 Nowak-Gottl U, Rath B, Binder M et al.. Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy.  Haematologica. 1995;  80 451-453
  PubMedGoogle Scholar
• 49 Das P, Carcao M, Hitzler J. Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia.  Pediatr Blood Cancer. 2006;  47 206-209
  CrossrefPubMedGoogle Scholar

Anthony K.C Chan

3N27D, McMaster University

1200 Main Street West, Hamilton, Ontario, Canada L8N 3Z5

Email: akchan@mcmaster.ca